

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human LYPD1 in direct ELISAs. In direct ELISAs, less than 1% cross-reactivity with recombinant human LYPD3 is observed.
Source	Polyclonal Sheep IgG
Purification	Antigen Affinity-purified
Immunogen	<i>E. coli</i> -derived recombinant human LYPD1 Cys54-Ser116 Accession # Q8N2G4
Conjugate	Alexa Fluor 405 Excitation Wavelength: 405 nm Emission Wavelength: 421 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
*Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.	

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Immunohistochemistry Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

LYPD1 (Ly6/PLAUR-domain containing protein 1; also Lynx2 and PHTS) is a 15-20 kDa member of the Ly6 family of GPI-anchored proteins. It is expressed on postmitotic neurons in multiple locations, performing multiple functions. Two suggested functions include the ability to 1) block cell proliferation, and 2) bind to acetylcholine receptors, promoting their desensitization. Human LYPD1 preproprecursor is 141 amino acids (aa) in length. It contains a signal sequence (aa 1-20), a 97 aa mature region (aa 21-117), and a cleavable prodomain that, when cleaved, generates a GPI-linked form (aa 118-141). The mature molecule contains one Ly6 domain (aa 25-107). There are multiple potential isoform variants. One possesses an alternative start site at Met53, a second contains a 21 aa substitution for aa 1-5, a third shows a 21 aa substitution for aa 64-141, and a fourth possesses a 29 aa substitution for aa 65-141. Over aa 54-116, human and mouse LYPD1 are identical in aa sequence.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.